Targeting CD30 using brentuximab vedotin in the treatment of Hodgkin lymphoma

Cancer Journal (United States)

Volumn 22, Issue 1, 2016, Pages 23-26

  Alperovich, Anna ^a   Younes, Anas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

antibody drug conjugates (ADCs); brentuximab vedotin; CD30 receptors; therapeutic target

Indexed keywords

BENDAMUSTINE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; DOXORUBICIN; GEMCITABINE; NAVELBINE; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

HODGKIN DISEASE; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; RETREATMENT; TREATMENT OUTCOME;

ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY; RETREATMENT; TREATMENT OUTCOME;

EID: 84957688772     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000168     Document Type: Review

References (18)

1. Falini B, Pileri S, Pizzolo G, CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995; 85: 1-14.
2. Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010; 363: 1812-1821.
3. Younes A, Gopal AK, Smith SE, Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30: 2183-2189.
4. Gopal AK, Ramchandren R, O'Connor OA, Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012; 120: 560-568.
5. Younes A, Connors JM, Park SI, Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013; 14: 1348-1356.
6. Connors JM, Ansell S, Park SI, Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long term outcomes. Blood. 2014; 124: 292.
7. Eichenauer DA, Plütschow A, Kreissl S, Targeted Beacopp variants in patients with newly diagnosed advanced stage classical hodgkin lymphoma: interim results of a randomized phase II study. Blood. 2013; 122: 4344.
8. Chen RW, Palmer J, Martin P, Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood. 2014; 124: 501.
9. Forero-Torres A, Holkova B, Sharman JP, Brentuximab vedotin monotherapy and in combination with dacarbazine in frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a phase 2 study. Blood. 2014; 124: 294.
10. Abramson JS, Arnason JE, LaCasce AS, Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: a phase II trial. J Clin Oncol. 2015; 33.
11. Kumar A, Yahalom J, Schoder H, Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 Gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma. Blood. 2014; 124: 3085.
12. Moskowitz AJ, Schoder H, Yahalom J, PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015; 16: 284-292.
13. LaCasce A, Bociek RG, Matous J, Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. Blood. 2014; 124: 293.
14. Michallet AS, Guillermin Y, Deau B, Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica. 2015; 100: e269-e271.
15. Moskowitz CH, Nademanee A, Masszi T, Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2015; 385: 1853-1862.
16. Park SI, Richards KL, Olajide O, A phase 2 trial of induction chemotherapy with ABVD followed by brentuximab vedotin consolidation in patients with previously untreated non-bulky stage I or II Hodgkin lymphoma. Blood. 2014; 124: 4431.
17. Zinzani PL, Luminari S, Merli F, Brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma. A pilot phase II study. Blood. 2014; 124: 3088.
18. Forero-Torres A, Holkova B, Goldschmidt J, Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015; 126: 2798-2804.